BACKGROUND: MicroRNAs (miRNAs) are small noncoding RNAs that regulate the expression of approximately 60% of all human genes. They play important roles in numerous cellular processes, including development, proliferation, and apoptosis. Currently, it is believed that miRNAs elicit their effect by silencing the expression of target genes. In this study, the authors demonstrated that miRNA-205 (miR-205) induced the expression the interleukin (IL) tumor suppressor genes IL24 and IL32 by targeting specific sites in their promoters. METHODS: The methods used in this study included transfection of small RNAs; quantitative real-time polymerase chain reaction; in situ hybridization; fluorescence-labeled in situ hybridization; cell cycle, apoptosis, cell viability, migratory, clonability, and invasion assays; immunoblotting; and luciferase reporter, nuclear run-on, and chromatin immunoprecipitation assays. RESULTS: The results revealed that miR-205 was silenced in prostate cancer. Its re-expression induced apoptosis and cell cycle arrest. It also impaired cell growth, migration, clonability, and invasiveness of prostate cancer cells. Micro-RNA-205 induced the expression of tumor suppressor genes IL24 and IL32 at both the messenger RNA and protein levels. The induction of in vitro transcription and enrichment of markers for transcriptionally active promoters in the IL24 and IL32 genes was observed in response to miR-205. CONCLUSIONS: In this study, a new function for miR-205 was identified that specifically activated tumor suppressor genes by targeting specific sites in their promoters. These results corroborate a newly identified function that miRNAs have in regulating gene expression at the transcriptional level. The specific activation of tumor suppressor genes (eg, IL24, IL32) or other dysregulated genes by miRNA may contribute to a novel therapeutic approach for the treatment of prostate cancer.
BACKGROUND: MicroRNAs (miRNAs) are small noncoding RNAs that regulate the expression of approximately 60% of all human genes. They play important roles in numerous cellular processes, including development, proliferation, and apoptosis. Currently, it is believed that miRNAs elicit their effect by silencing the expression of target genes. In this study, the authors demonstrated that miRNA-205 (miR-205) induced the expression the interleukin (IL) tumor suppressor genes IL24 and IL32 by targeting specific sites in their promoters. METHODS: The methods used in this study included transfection of small RNAs; quantitative real-time polymerase chain reaction; in situ hybridization; fluorescence-labeled in situ hybridization; cell cycle, apoptosis, cell viability, migratory, clonability, and invasion assays; immunoblotting; and luciferase reporter, nuclear run-on, and chromatin immunoprecipitation assays. RESULTS: The results revealed that miR-205 was silenced in prostate cancer. Its re-expression induced apoptosis and cell cycle arrest. It also impaired cell growth, migration, clonability, and invasiveness of prostate cancer cells. Micro-RNA-205 induced the expression of tumor suppressor genes IL24 and IL32 at both the messenger RNA and protein levels. The induction of in vitro transcription and enrichment of markers for transcriptionally active promoters in the IL24 and IL32 genes was observed in response to miR-205. CONCLUSIONS: In this study, a new function for miR-205 was identified that specifically activated tumor suppressor genes by targeting specific sites in their promoters. These results corroborate a newly identified function that miRNAs have in regulating gene expression at the transcriptional level. The specific activation of tumor suppressor genes (eg, IL24, IL32) or other dysregulated genes by miRNA may contribute to a novel therapeutic approach for the treatment of prostate cancer.
Authors: A M Mhashilkar; R D Schrock; M Hindi; J Liao; K Sieger; F Kourouma; X H Zou-Yang; E Onishi; O Takh; T S Vedvick; G Fanger; L Stewart; G J Watson; D Snary; P B Fisher; T Saeki; J A Roth; R Ramesh; S Chada Journal: Mol Med Date: 2001-04 Impact factor: 6.354
Authors: Z Z Su; M T Madireddi; J J Lin; C S Young; S Kitada; J C Reed; N I Goldstein; P B Fisher Journal: Proc Natl Acad Sci U S A Date: 1998-11-24 Impact factor: 11.205
Authors: Rajagopal Ramesh; Abner M Mhashilkar; Fumihiro Tanaka; Yuji Saito; Cynthia D Branch; Kerry Sieger; John B Mumm; Alexis L Stewart; Amelie Boquoi; Laure Dumoutier; Elizabeth A Grimm; Jean-Christophe Renauld; Sergei Kotenko; Sunil Chada; Amelia Boquio Journal: Cancer Res Date: 2003-08-15 Impact factor: 12.701
Authors: Sunil Chada; R Bryan Sutton; Suhendan Ekmekcioglu; Julie Ellerhorst; John B Mumm; Wolfgang W Leitner; Heng-Yin Yang; Aysegul A Sahin; Kelly K Hunt; Kerry L Fuson; Nancy Poìndexter; Jack A Roth; Rajagopal Ramesh; Elizabeth A Grimm; Abner M Mhashilkar Journal: Int Immunopharmacol Date: 2004-05 Impact factor: 4.932
Authors: Bas Heinhuis; Marije I Koenders; Wim B van den Berg; Mihai G Netea; Charles A Dinarello; Leo A B Joosten Journal: J Biol Chem Date: 2011-12-27 Impact factor: 5.157